Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84040 | 0.93 | RAB9A (0.62) | MEN1KMT2ARAB9ACA1CA2 | |
| Ammonia Solution, Strong SCHEMBL28016105 | 0.90 | RAB9A (0.60) | MEN1KMT2ARAB9ACA1CA2 | |
| SCHEMBL4366979 | 0.90 | ALDH1A1 (0.48) | MEN1KMT2ARAB9AALDH1A1TDP1 | |
| SCHEMBL15849015 | 0.90 | ALDH1A1 (0.48) | MEN1KMT2ARAB9AALDH1A1TDP1 | |
| SCHEMBL487342 | 0.86 | RAB9A (0.56) | MEN1KMT2ARAB9ACA1CA2 | |
| SCHEMBL28330426 | 0.86 | RAB9A (0.56) | MEN1KMT2ARAB9ACA1CA2 | |
| SCHEMBL27048202 | 0.85 | PKM (0.66) | MEN1KMT2ARAB9ACA1CA2 | |
| SCHEMBL19203156 | 0.85 | HPGD (0.61) | MEN1KMT2ARAB9ACA1CA2 | |
| SCHEMBL13995154 | 0.84 | SMN1; SMN2 (0.68) | MEN1KMT2ALTA4HALDH1A1SMN1; SMN2 | |
| Boric Acid SCHEMBL14874706 | 0.84 | RAB9A (0.59) | MEN1KMT2ARAB9ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059107-A1 | IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9394261-B2 | Aryl amine substituted pyrimidine and quinazoline and their use as anticancer drugs | NATIONAL YANG-MING UNIVERSITY (TW) | 2016-07-19 | — | — | US | disclosed |
| US-20150246891-A1 | ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANCER DRUGS | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-09-03 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | MEN1 479/4885KMT2A 482/4885RAB9A 2323/4885 |
| US-20150246891-A1 | ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANCER DRUGS | EGFR, ERBB4, ERBB2 | MEN1 3727/4885KMT2A 2105/4885RAB9A 496/4885 |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | MEN1 3389/4885KMT2A 2979/4885RAB9A 974/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | MEN1 3562/4885KMT2A 1186/4885RAB9A 2803/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | MEN1 510/4885KMT2A 1311/4885RAB9A 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.